Education
About Us
Working with TipRanks
Follow Us
Aerovate Therapeutics (AVTE)
NASDAQ:AVTE
Total Valuation
Aerovate Therapeutics has a market cap or net worth of $10.34M. The enterprise value is -$1.40M.
Market Cap$10.34M
Enterprise Value-$1.40M
Share Statistics
Aerovate Therapeutics has 828,143 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding828,143
Owned by Insiders51.18%
Owned by Institutions0.26%
Financial Efficiency
Aerovate Therapeutics’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -97.05%.
Return on Equity (ROE)-0.91
Return on Assets (ROA)-0.87
Return on Invested Capital (ROIC)-97.05%
Return on Capital Employed (ROCE)-0.98
Revenue Per Employee0.00
Profits Per Employee-17.41M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aerovate Therapeutics is -1.09. Aerovate Therapeutics’s PEG ratio is 0.07.
PE Ratio-1.09
PS Ratio0.00
PB Ratio0.99
Price to Fair Value0.99
Price to FCF-1.06
Price to Operating Cash Flow-1.06
PEG Ratio0.07
Income Statement
In the last 12 months, Aerovate Therapeutics had revenue of 0.00 and earned -69.63M in profits. Earnings per share was -2.44.
Revenue0.00
Gross Profit0.00
Operating Income-74.60M
Pretax Income-69.57M
Net Income-69.63M
EBITDA-74.31M
Earnings Per Share (EPS)-2.44
Cash Flow
In the last 12 months, operating cash flow was -49.90M and capital expenditures 0.00, giving a free cash flow of -49.90M billion.
Operating Cash Flow-49.90M
Free Cash Flow-49.90M
Free Cash Flow per Share-60.26
Dividends & Yields
Aerovate Therapeutics pays an annual dividend of $2.4, resulting in a dividend yield of ―
Dividend Per Share$2.4
Dividend Yield―
Payout Ratio-7.83%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.58
52-Week Price Change-83.45%
50-Day Moving Average9.39
200-Day Moving Average8.56
Relative Strength Index (RSI)79.63
Average Volume (3m)35.59K
Important Dates
Aerovate Therapeutics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 26, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend DateApr 29, 2025
Financial Position
Aerovate Therapeutics as a current ratio of 20.93, with Debt / Equity ratio of 0.42%
Current Ratio20.93
Quick Ratio20.93
Debt to Market Cap0.00
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aerovate Therapeutics has paid 55.00K in taxes.
Income Tax55.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Aerovate Therapeutics EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -0.60.
EV to Sales0.00
EV to EBITDA-0.57
EV to Free Cash Flow-0.60
EV to Operating Cash Flow-0.60
Balance Sheet
Aerovate Therapeutics has $76.21M in cash and marketable securities with $312.00K in debt, giving a net cash position of -$75.90M billion.
Cash & Marketable Securities$76.21M
Total Debt$312.00K
Net Cash-$75.90M
Net Cash Per Share-$91.65
Tangible Book Value Per Share$2.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aerovate Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast44.04%